Clinical Trial Update: Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp [Phase 4]

View source ↗

Summary

Phase 4 post-marketing study of micafungin for fungal infections caused by Candida and Aspergillus spp. has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis
• Candidiasis

Drugs mentioned

• Micafungin (micafungin)

Snippet

Sponsor: Astellas Pharma China, Inc. | Conditions: Aspergillosis, Candidiasis | Phase 4 | Status: TERMINATED